Transition Therapeutics Appoints Carl Damiani as Chief Operating Officer

15-Jul-2014 - Canada

Transition Therapeutics Inc. Chairman and Chief Executive Officer, Dr. Tony Cruz announced that Carl Damiani has been appointed to the role of Chief Operating Officer of Transition.

"This appointment reflects Mr. Damiani's broader leadership role in overseeing Transition employees and operations in Toronto, San Francisco and Ireland, as well as advancing our late stage neuropsychiatric drug candidate, ELND005, for AD patients, the phase 2 diabetes drug candidate TT-401 partnered with Lilly, and growing our pipeline with assets acquired from pharma partners", said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition.

Since joining Transition in 2003, Mr. Damiani has held the roles of Vice-President of Business Development and Director of Business Development.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances